Aoun supervises the launch of the first export of insulin pens to Saudi Arabia – Algerian Dialogue

Today, Sunday, at the Novo Nordisk industrial site in Boufarik (Blida Province), Minister of Industry and Pharmaceutical Production, Ali Aoun, supervised the launch of the first export of insulin pens to the Kingdom of Saudi Arabia.
The Minister explained in a speech he delivered, in the presence of the Chairman of the Algerian Economic Renewal Council, Kamal Moulay, the Danish Ambassador to Algeria, Catherine From Heuer, and the local authorities, that this shipment, which will be issued in three stages and includes 2.5 million insulin pens, with a turnover estimated at 11 million euros, comes To be fully consistent with the policy of diversifying the national economy and promoting exports called for by the President of the Republic, Mr. Abdelmadjid Tebboune.

The Minister appreciated the efforts made by the company, which he said “was able to break into a country in which it is very difficult to position itself in the field of medicine, on the one hand, and win the bet of providing various types of insulin for the benefit of diabetics in Algeria and sparing them the problem of drug scarcity that was previously on offer.”

He recorded in this regard that “for the first time during the month of Ramadan, the problem of insulin scarcity did not arise in Algeria, thanks to the efforts of all insulin producers, such as Novo Nordisk and others.”

Mr. Aoun added that “insulin medicine manufactured in Algeria, in general, is of unquestionable quality, despite what is said,” stressing that, during the year 2024 and in the coming years, “no scarcity of any type of insulin will be recorded, in accordance with the obligations of the producers.” .

The minister reassured by saying that “Algeria currently has sufficient stock for a period of 6 months, for a number of types of insulin, at the level of producers, and a similar stock at the level of distribution centers,” calling on those in charge of the company to redouble efforts and move to the “quality” stage and go to search for Other foreign markets to contribute to reducing the import bill and promoting exports.

For her part, General Director of Novo Nordisk Algeria, Malika Dergal, stated that the national product contributes to Algeria’s health and industrial sovereignty by ensuring continuity of supply to Algerian patients, pointing out that local production “conforms to the highest quality standards.”

She revealed that the company, with its two production sites, one of which is located in Tizi Ouzou and the other in Boufarik, aspires to make Algeria in 2025 a leader in insulin and metformin exports, by exporting its products to Tunisia, Libya and Egypt, with a turnover estimated at more than 25 million euros.

In November 2023, from its production site in Tizi Ouzou, this institution exported the first shipment of metformin to Libya.

Dergal stated that Novo Nordisk’s contribution to “the development of the health system in Algeria will continue thanks to the modern and innovative treatments that we propose in the fields of diabetes, obesity and rare diseases, as well as in citizen initiatives.”

The Boufarik production site, which was inaugurated in January 2023, specializes in manufacturing Flexpen insulin pens, while the Tizi Ouzou production site, which came into operation in 2006, manufactures dry forms of oral antidiabetics.

All reactions:

289Algerian citizen marshal et 288 autres personnes